Vertex Pharmaceuticals Incorporated NMS · VRTX

Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?

The Motley Fool · 8d ago

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

The Motley Fool · 9d ago

Why This Pharmaceutical Stock Jumped Close to 100% This Week

The Motley Fool · 11d ago

Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?

The Motley Fool · 11d ago

Vertex’s Crinetics Deal Balances Growth with Integration Risk

Investing.com · 13d ago

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

The Motley Fool · 13d ago

Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.

The Motley Fool · 13d ago

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 15d ago

FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

GlobeNewswire Inc. · 19d ago

Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

GlobeNewswire Inc. · 28d ago

Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders

Benzinga · 40d ago

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

The Motley Fool · 43d ago

CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

The Motley Fool · 48d ago

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?

The Motley Fool · 56d ago

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?

The Motley Fool · 70d ago

Global Personalized Medicine to Transform Modern Healthcare and Cross USD 1 Trillion by 2034 | DelveInsight

GlobeNewswire Inc. · 71d ago

Is This Millionaire-Maker Biotech Stock a Buy Right Now?

The Motley Fool · 76d ago

Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying?

The Motley Fool · 80d ago

Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering

The Motley Fool · 82d ago

What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.

The Motley Fool · 82d ago

Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?

The Motley Fool · 82d ago

IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight

GlobeNewswire Inc. · 83d ago

3 Healthcare Stocks With the Most Durable Competitive Moats

The Motley Fool · 89d ago

CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?

The Motley Fool · 91d ago

Is Vertex Pharmaceuticals' Empire in Trouble?

The Motley Fool · 96d ago